TScan Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCRX research report →
Companywww.tscan.com
TScan Therapeutics, Inc. , a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.
- CEO
- Gavin MacBeath
- IPO
- 2021
- Employees
- 200
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $60.74M
- P/E
- -1.04
- P/S
- 6.65
- P/B
- 1.33
- EV/EBITDA
- 0.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.41%
- Op Margin
- -1408.73%
- Net Margin
- -1360.61%
- ROE
- -91.94%
- ROIC
- -67.93%
Growth & Income
- Revenue
- $10.32M · 266.65%
- Net Income
- $-129,766,000 · -1.78%
- EPS
- $-1.00 · 12.28%
- Op Income
- $-135,813,000
- FCF YoY
- -21.87%
Performance & Tape
- 52W High
- $2.57
- 52W Low
- $0.88
- 50D MA
- $1.12
- 200D MA
- $1.35
- Beta
- 1.06
- Avg Volume
- 874.94K
Get TickerSpark's AI analysis on TCRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 20, 26 | Amello Jason | other | 350,000 |
| Jan 20, 26 | MacBeath Gavin | other | 1,165,000 |
| Jan 20, 26 | Dworak Leiden | other | 100,000 |
| Jan 20, 26 | Louis Chrystal | other | 420,000 |
| Jan 20, 26 | ZDRAVESKI ZORAN | other | 350,000 |
| Dec 23, 25 | Lynx1 Capital Management LP | buy | 6,232 |
| Dec 22, 25 | Lynx1 Capital Management LP | buy | 75,500 |
| Dec 19, 25 | Lynx1 Capital Management LP | buy | 80,069 |
| Aug 14, 25 | Dworak Leiden | other | 46,875 |
| Aug 14, 25 | Dworak Leiden | other | 25,000 |
Our TCRX Coverage
We haven't published any research on TCRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TCRX Report →